Member Info for inanaco

the point being its NOT the vaccine doing the Killing ....

The vaccine is only a primer of existing T cells ... and activating them

which is why i keep highlighting how Keytruda works

It blocks the PD-1 on the T cell ....

Its called Consensus

activation of a T cell ...

"cross presentation"

so if everything you read in NON Scancell papers indicate Scancell has the right method .. how can i find the mechanism of Failure ... ? or even identify a method of failure

I can't ...

C7 you cannot ramp "factual" science ....

which is why i keep saying ... "" what is the mechanism of failure ""

which trial has failed

SCIB1 ....

or

Keytruda

because of the mechanism of Keytruda it has to work with T cells its proven .... nobody can argue against that

so is SCIB1 t cells proven to elicit an immune response .......... yes IFN detected specific to a target antigen
which only happens when a T cell binded with the target cell . and killed it

IMM already had proof that the Placebo effect skewed results in previous trails ... and its a completely different class of drug to Scancell ... you just cannot compare ...

the Biggest mistake Investors are making is confusing a Scancell CD8 T cell with every other CD8 T cell ... they are all the same

the only difference is the way they are "activated"

and just to show how Complex this arena is ...

https://pdfs.semanticscholar.org/d3d3/c533b6bf7f18d58e4d4dea3720a08a4e4427.pdf

C7 ... true value

Just pull off all my posts on SCIB1 over the last week .. string them together without the interruptions and you will see a full risk analysis of just SCIB1 demonstrating real value on its own ...

the Rest of the portfolio is a bonus

The reason why i just stick with just SCIB1 is we have that """"clear clinical data in Patients"" that links to PD-1 (keytruda) mechanism of action as a synergy of product

as PD-1 is current standard of care ... it instantly becomes "commercial" as its not in competition .

now other products are being tested with Keytruda .. but many are not "incompatible" with the further use of the vaccine in a Tri format ...

which is what i have tried to get across in the posts ...

Cheeky Devil and the Devil ... LOL

Me ... Innocent .... even got a smoothie named after me

Yea .. Tusk thinks I belong in Hell.......

Oh dear.... The Space Cadets already think that

my new mobile 666

it's no worries ........... we do have an acceptable "back Stop" SCIB1 ..

check out Tom Tom ... lots of avenues in Oxford C7 ..... no idea mate .. its wait RNS

i think the TCR deal will provide the liquidity ... but have to wait

No Crumbs ...

Bermuda did not look what i had written """" The modi1 trial splits into 3 seperate target trials under one umbrella""""

""" one umbrella"""" ... on ADFVN he is now waffling on about 3 separate trials . costing 3 x set up cost

I suppose if you don't read "umbrella" you could indeed get carried away with excitement ....

well ...you have upset Bermuda now ...

i will stick with Factorial design ...

sounds nice ... !

looked at the wrong line that was our combo trial .. scib1 opps !

well scancell call it a Combination trial ...

https://www.scancell.co.uk/file-manager/PDFs/scancell-presentation-feb18v2.pdf

had this debate before it did not end well !!!

The modi1 trial splits into 3 seperate target trials under one umbrella .. the single trial refers only to the phase 1 part

60% now goes to 99% sure

CD25+CD4+ Tregs potently suppress proliferation of other CD4+ and CD8+ T cells when Treg and responder populations are """"""""""co-cultured and stimulated with specific antigen"""""""""""""" or a polyclonal TCR stimulator (such as anti-CD3 mAb) in the presence of antigen-presenting cells (APCs). CD25+CD4+ Tregs also suppress cytokine production (especially IL-2 production) by CD4+ and CD8+ responder T cells and their effector activities such as CD8+ T cell cytotoxicity.

It gives you an idea why we don't want them activated by the vaccine

""" Regulatory T cells: how do they suppress immune responses """

https://academic.oup.com/intimm/article/21/10/1105/883857

i have no worries at all ..

if the epitope is on the cancer and the T cell TCR ......... the T cell does not wake up and say ... nah ! not today ..

Overview
The EasySep™ Human Pan-CD25 Positive Selection and Depletion Kit is designed to deplete CD25+ cells from fresh peripheral blood mononuclear cells or lysed leukapheresis samples. CD25+ cells are targeted with Tetrameric Antibody Complexes recognizing CD25 and dextran-coated magnetic particles. Labeled cells are separated using an EasySep™ magnet without the use of columns. Labeled cells remain in the tube while unlabeled cells are poured off. The CD25 antigen is expressed on regulatory T cells and activated T and B cells.

https://www.stemcell.com/easysep-human-cd25-depletion-kit.html

need to research it a lot more as the Cd4+cd25 T cell is a regulatory cell so i assume that its effects need to be dampened .... but i am 60% sure the vaccine solves this by the TH1 activation ... back to this phenotype again

see Lindy is only testing the peptides of the vaccine not the vaccine itself ... so the phenotype is not controlled